Is budesonide oral suspension (Eohilia) a cough suppressant or an anti-inflammatory?

Budesonide oral suspension (Eohilia) is not a cough suppressant in the traditional sense, but a glucocorticoid drug with anti-inflammatory effects, mainly used to treat eosinophilic esophagitis (EoE). EoE is a chronic inflammatory disease caused by an immune response, characterized by massive infiltration of eosinophils in the esophageal wall, leading to dysphagia, retrosternal burning, and reflux-like discomfort. The core mechanism of action of Eohilia is to inhibit the inflammatory response through budesonide, thereby improving the structure and function of the esophageal mucosa. Its liquid can evenly cover the esophageal wall when swallowed, forming a continuous local anti-inflammatory protective layer, which helps reduce the infiltration of inflammatory cells, promote tissue repair, and improve the compliance and comfort of the esophagus. This is especially important for patients who have been troubled by EoE for a long time.

Unlike cough medicines,Eohilia does not directly act on the respiratory tract or cough reflex center, and its therapeutic target is concentrated on the esophagus rather than the bronchi. Therefore, if a patient has cough symptoms, it is often an indirect cough caused by esophageal inflammation or acid reflux. By controlling inflammation, Eohilia can indirectly relieve related coughs, but it does not have a direct antitussive effect. Some clinical studies have shown that long-term use of Eohilia can not only improve swallowing function, but also reduce eosinophil infiltration in the esophageal mucosa, thereby reducing indirect cough, throat irritation and reflux-related symptoms.

In addition,Eohilia's drug design is characterized by high local efficacy and low systemic exposure, which means that even with long-term use, the risk of systemic glucocorticoid side effects is relatively low. The medicinal liquid is in the form of an oral suspension. Shake well and take it after taking it to form an effective anti-inflammatory layer on the esophageal surface. After swallowing, the medicine gradually returns to a thicker state to extend the contact time with the esophageal mucosa and improve the therapeutic effect.

Reference materials:https://www.drugs.com